Adam Zamecnik
Reporter
Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.
Latest From Adam Zamecnik
Newbury Secures Approval For Victoza Generic In Denmark
Only days after the EU-wide decentralized approval of Adalvo’s Victoza generic, Newbury broke news with the greenlighting of its own Victoza rival in Denmark.
Teva Launches Victoza Rival In The US
Several years after securing a settlement with Novo Nordisk, Teva has launched its Victoza authorized generic in the US ahead of competition
Kidswell And Chiome Team Up On Biosimilar Development
In an effort to set themselves apart from other Japanese companies, Kidswell and Chiome have signed a deal focused on the co-development of new biosimilars and profit sharing.
British Columbia Saves Over $700m From Biosimilar Switching
Launched in 2019, the province’s biosimilar switching initiative has saved over $732m, which were reinvested into expanded coverage for drugs, and sparked a wave of similar projects in other Canadian regions.
Adalvo Secures First EU Approval For Victoza Rival
Adalvo has secured the first-ever approval of a Victoza rival in the EU, paving the way for future launches in the key market ahead of competitors.
‘A New Era’: What Next For CRISPR Gene Editing After First Approval?
Emerging out of a landmark 2023, CRISPR companies and researchers are pushing in vivo therapies and other approaches closer to the clinic and potential approval.